Methods We conducted detailed literature searches of MEDLINE, EMBASE, PsycInfo and the Cochrane library, searched trial registration sites, contacted authors if results have not been published and hand searched reference lists. Three categories of search terms were used; paediatric, CFS/ME and recovery.

Inclusion criteria Randomised controlled trials or observational studies of participants <19 years old with a diagnosis of CFS/ME, related to a Western Health Care system, some measure of recovery (partial or full) reported and the time taken to reach it.

Results 21 papers were identified. The study populations ranged from 1 to 64 participants, their duration of illness ranged from 3 months to 7 years between studies and also showed great variety within each study. Some studies used a single measurement outcome for recovery, others measured several and some integrated multiple outcomes to formulate one value for recovery. The recovery rate ranged from 25–100% in those accessing treatment and 4.5–100% in those without specialist care. School attendance was the most common measurement outcome ($n = 11$), of which 4 of these combined this with at least one other measure. 7 studies measured physical ability as an outcome, 8 used fatigue and 9 measured a global improvement that was either self-rated or qualitatively assessed by an investigator. 2 studies described recovery as no longer fulfilling the diagnostic criteria.

Conclusion Recovery rates are relatively high in children accessing specialist treatment however, the discrepancies between the measurement outcomes, makes interpretation of recovery rates difficult.

G359

THE DIAGNOSIS, MANAGEMENT AND OUTCOMES OF PAEDIATRIC EOSINOPHILIC OESOPHAGITIS: A FIVE-YEAR RETROSPECTIVE ANALYSIS OF THE WEST OF SCOTLAND POPULATION

¹M Goddard, ¹DM Flynn, ²D Penman, ¹AR Barclay, ¹H Duncan, ¹RK Russell, ¹R Hansen. ¹Paediatric Gastroenterology, Yorkhill Hospital, Glasgow, UK; ²Paediatric and Perinatal Pathology, Southern General Hospital, Glasgow, UK

10.1136/archdischild-2015-308599.315

Background Eosinophilic oesophagitis (EO) is a recently described allergic condition characterised by oesophageal dysmotility with progression to stricture formation in severe cases. Diagnosis is histological, based on >15 per high-powered field in oesophageal biopsies. Treatment options remain limited to dietary modification (including elemental feeds), proton pump inhibitors (PPI) and topical/systemic steroids. There is sparse population data on the condition.

To report demographic data on children with EO, establish the current burden of disease and review effectiveness of treatments with clinical and histopathological outcomes.

Methods All patients diagnosed with EO between 2008–2013 in RHSC Glasgow were retrospectively identified by joint review of all oesophageal histopathology reports ($n = 1060$) with a Consultant Paediatric Pathologist (DP) and findings correlated with clinical symptoms, treatment and outcomes. Data was analysed using Microsoft Excel 2007 and SPSS version 22.0.

Results Within the West of Scotland 30 children (mean age 9.1, range 0.7–15.2) were diagnosed with EO between January 2008 and May 2013 with no obvious increase in annual incidence. 22 (73%) were male. The most common presenting symptoms were abdominal pain (43%), vomiting (37%) and dysphagia (33%), with food bolus obstruction in 27%. Most (77%) had concurrent atopic disease. At diagnosis the mean number of

oesophageal eosinophils per high-powered field was 61, ascertained with a mean of 5 biopsies from 3 different oesophageal regions. The mean peripheral eosinophil count at diagnosis was 1.8 (range 0.0–27.0).

PPIs were clinically effective in 19/21 (70%) patients and 14/16 showed histological improvement. All 17 patients receiving dietary therapy demonstrated clinical improvement and 14/15 showed histological improvement; 11 (40%) had topical steroids, clinically effective in 10/11 patients with 7/9 showing histological improvement. However, 4 (13%) progressed to oral steroids. There was considerable overlap between treatments. At one year follow-up 93% were clinically improved and 86% showed endoscopic improvement.

Conclusions The total numbers of patients diagnosed was surprisingly small. Whilst treatment with PPI is effective, most patients also required dietary or steroid therapy. A significant number required oral steroids. A departmental guideline is being developed on the basis of these results and further work is required to establish frequency of repeat endoscopy.

G360

THE EPIDEMIOLOGY AND OUTCOME OF BILIARY ATRESIA IN SCOTLAND 2002–2013

¹E Sutton, ²P Henderson, ³R Tayler, ²K Fraser, ²J Cowieson, ⁴D Goudie, ⁵K McIntyre, ⁵D Kastner-Cole, ⁶C Cameron, ⁶S Loganathan, ⁷P Rogers, ⁷D Mitchell, ⁸C Delahunty, ²AR Barclay, ²R Hansen. ¹University of Glasgow, Glasgow, UK; ²Paediatric Gastroenterology, Yorkhill Hospital, Glasgow, UK; ³Paediatric Hepatology, Leeds Children's Hospital, Leeds, UK; ⁴Paediatrics, Raigmore Hospital, Inverness, UK; ⁵Paediatrics, Ninewells Hospital, Dundee, UK; ⁶Paediatric Gastroenterology, Royal Aberdeen Children's Hospital, Aberdeen, UK; ⁷Paediatric Gastroenterology, Royal Hospital for Sick Children, Edinburgh, UK; ⁸Paediatrics, Wishaw General Hospital, Wishaw, UK

10.1136/archdischild-2015-308599.316

Background Biliary atresia (BA) is a rare, poorly understood liver disease of infancy that is fatal if not treated through early biliary drainage via the Kasai procedure. BA surgery was rationalised to three UK centres in 2002 following data supporting improved outcomes in institutions performing >5 Kasai per year. We have previously shown that outcomes in Scottish children were worse than expected in the years following initial rationalisation.

Aims We aimed to expand the post-rationalisation cohort of BA cases in Scotland to examine epidemiology and outcomes.

Methods Outcomes of the previously published 2002–2009 incident cohort was first expanded. New Scottish incident cases of BA born between 2010–2013, were obtained using data from specialist nurse/team knowledge. New data collection focussed on demographics, details of Kasai and outcomes (particularly 2 year transplant-free survival [2YTFS]). Accurate regional and national population data was obtained from the General Register Office for Scotland and statistics performed in R with Poisson regression analysis for incidence trends.

Results 48 infants were initially identified, of whom 5 were excluded from outcome analysis (three with Kasai performed in Edinburgh, one with <1 yr follow-up post-Kasai and one born outside Scotland). Three infants required immediate liver transplantation; 43 infants underwent Kasai. Median age at Kasai in the full cohort was 55 days (range 19–96) and showed significant improvement from 61 days in 2002–2009 to 49 days in 2010–2013 ($p < 0.0001$). Of those with available data, 45% cleared their jaundice (bilirubin <20 $\mu\text{mol/l}$) six months post-Kasai; 2YTFS was 40%. BA incidence in Scotland was 0.68/10,000 live births and appeared stable (0.66/10,000 in